RU2020132924A - Терапевтические клеточные системы и способы лечения рака и инфекционных заболеваний - Google Patents
Терапевтические клеточные системы и способы лечения рака и инфекционных заболеваний Download PDFInfo
- Publication number
- RU2020132924A RU2020132924A RU2020132924A RU2020132924A RU2020132924A RU 2020132924 A RU2020132924 A RU 2020132924A RU 2020132924 A RU2020132924 A RU 2020132924A RU 2020132924 A RU2020132924 A RU 2020132924A RU 2020132924 A RU2020132924 A RU 2020132924A
- Authority
- RU
- Russia
- Prior art keywords
- cell
- nuclear
- exogenous stimulatory
- polypeptide
- free cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 48
- 206010028980 Neoplasm Diseases 0.000 title claims 18
- 201000011510 cancer Diseases 0.000 title claims 14
- 208000035473 Communicable disease Diseases 0.000 title claims 6
- 230000001225 therapeutic effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 154
- 229920001184 polypeptide Polymers 0.000 claims 144
- 102000004196 processed proteins & peptides Human genes 0.000 claims 144
- 108090000765 processed proteins & peptides Proteins 0.000 claims 144
- 230000004936 stimulating effect Effects 0.000 claims 118
- 210000000267 erythroid cell Anatomy 0.000 claims 36
- 102000003812 Interleukin-15 Human genes 0.000 claims 34
- 108090000172 Interleukin-15 Proteins 0.000 claims 34
- 230000004927 fusion Effects 0.000 claims 26
- 108010053727 Interleukin-15 Receptor alpha Subunit Proteins 0.000 claims 23
- 239000012634 fragment Substances 0.000 claims 18
- 102000013462 Interleukin-12 Human genes 0.000 claims 16
- 108010065805 Interleukin-12 Proteins 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 210000002865 immune cell Anatomy 0.000 claims 15
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 12
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 108010082808 4-1BB Ligand Proteins 0.000 claims 11
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 11
- 210000000822 natural killer cell Anatomy 0.000 claims 11
- 102000043129 MHC class I family Human genes 0.000 claims 10
- 108091054437 MHC class I family Proteins 0.000 claims 10
- 102100029740 Poliovirus receptor Human genes 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 230000000638 stimulation Effects 0.000 claims 8
- 102000003810 Interleukin-18 Human genes 0.000 claims 7
- 108090000171 Interleukin-18 Proteins 0.000 claims 7
- 230000004913 activation Effects 0.000 claims 7
- 102100035716 Glycophorin-A Human genes 0.000 claims 6
- 108091005250 Glycophorins Proteins 0.000 claims 6
- 229920002971 Heparan sulfate Polymers 0.000 claims 6
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims 6
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 6
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims 6
- -1 NkP44L Proteins 0.000 claims 6
- 102100029197 SLAM family member 6 Human genes 0.000 claims 6
- 102100030584 Small integral membrane protein 1 Human genes 0.000 claims 6
- 101710200166 Small integral membrane protein 1 Proteins 0.000 claims 6
- 208000036142 Viral infection Diseases 0.000 claims 6
- 238000012258 culturing Methods 0.000 claims 6
- 108010048507 poliovirus receptor Proteins 0.000 claims 6
- 230000009385 viral infection Effects 0.000 claims 6
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 5
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 5
- 229940027941 immunoglobulin g Drugs 0.000 claims 5
- 102100036008 CD48 antigen Human genes 0.000 claims 4
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims 4
- 101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 claims 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 108010042653 IgA receptor Proteins 0.000 claims 4
- 102000000589 Interleukin-1 Human genes 0.000 claims 4
- 108010002352 Interleukin-1 Proteins 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 claims 4
- 241000700584 Simplexvirus Species 0.000 claims 4
- 108010074108 interleukin-21 Proteins 0.000 claims 4
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims 3
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 3
- 108010052199 HLA-C Antigens Proteins 0.000 claims 3
- 108010024164 HLA-G Antigens Proteins 0.000 claims 3
- 102000006992 Interferon-alpha Human genes 0.000 claims 3
- 108010047761 Interferon-alpha Proteins 0.000 claims 3
- 102000004856 Lectins Human genes 0.000 claims 3
- 108090001090 Lectins Proteins 0.000 claims 3
- 102000002356 Nectin Human genes 0.000 claims 3
- 108060005251 Nectin Proteins 0.000 claims 3
- 101150042088 UL16 gene Proteins 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 102000023732 binding proteins Human genes 0.000 claims 3
- 108091008324 binding proteins Proteins 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 239000002523 lectin Substances 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 2
- 241000700721 Hepatitis B virus Species 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 241001631646 Papillomaviridae Species 0.000 claims 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 claims 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000007159 enucleation Effects 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 210000000948 non-nucleated cell Anatomy 0.000 claims 2
- 210000001995 reticulocyte Anatomy 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 claims 1
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 1
- 108010075704 HLA-A Antigens Proteins 0.000 claims 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 claims 1
- 102100030703 Interleukin-22 Human genes 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 claims 1
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 102000045429 human PGK1 Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000001638 lipofection Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640530P | 2018-03-08 | 2018-03-08 | |
| US62/640,530 | 2018-03-08 | ||
| US201862660657P | 2018-04-20 | 2018-04-20 | |
| US62/660,657 | 2018-04-20 | ||
| US201862680490P | 2018-06-04 | 2018-06-04 | |
| US62/680,490 | 2018-06-04 | ||
| US201862692487P | 2018-06-29 | 2018-06-29 | |
| US62/692,487 | 2018-06-29 | ||
| US201862732050P | 2018-09-17 | 2018-09-17 | |
| US62/732,050 | 2018-09-17 | ||
| US201862757717P | 2018-11-08 | 2018-11-08 | |
| US62/757,717 | 2018-11-08 | ||
| PCT/US2019/021490 WO2019173798A1 (en) | 2018-03-08 | 2019-03-08 | Therapeutic cell systems and methods for treating cancer and infectious diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020132924A true RU2020132924A (ru) | 2022-04-11 |
Family
ID=65904565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020132924A RU2020132924A (ru) | 2018-03-08 | 2019-03-08 | Терапевтические клеточные системы и способы лечения рака и инфекционных заболеваний |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11141433B2 (enExample) |
| EP (1) | EP3762422A1 (enExample) |
| JP (1) | JP2021514665A (enExample) |
| KR (1) | KR20200140279A (enExample) |
| CN (1) | CN112105723A (enExample) |
| AU (1) | AU2019232012A1 (enExample) |
| CA (1) | CA3093387A1 (enExample) |
| IL (1) | IL277159A (enExample) |
| MX (1) | MX2020009359A (enExample) |
| RU (1) | RU2020132924A (enExample) |
| SG (1) | SG11202008261WA (enExample) |
| WO (1) | WO2019173798A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| CN112105723A (zh) | 2018-03-08 | 2020-12-18 | 鲁比厄斯治疗法股份有限公司 | 用于治疗癌症和传染病的治疗性细胞系统和方法 |
| EP3891269A1 (en) * | 2018-12-03 | 2021-10-13 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use |
| JP2022530130A (ja) | 2019-04-26 | 2022-06-27 | ルビウス セラピューティクス， インコーポレイテッド | 除核赤血球細胞を含む緩衝組成物 |
| IL288210B2 (en) | 2019-05-20 | 2026-03-01 | Cytune Pharma | Dosing regimens of IL-2/IL-15 beta-gamma receptor agonists for the treatment of cancer or infectious diseases |
| CN110777115B (zh) * | 2019-11-21 | 2020-08-21 | 北京启辰生生物科技有限公司 | 用于促进辅助T细胞产生TNF-α细胞因子的工程化DC细胞及方法 |
| JP2023512712A (ja) * | 2020-02-07 | 2023-03-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 除核細胞をバイオ操作するための方法および使用 |
| JP2023513263A (ja) * | 2020-02-10 | 2023-03-30 | ルビウス セラピューティクス， インコーポレイテッド | Ｈｌａ－ｇポリペプチドを含む操作された赤血球系細胞およびその使用方法 |
| CN111849896B (zh) * | 2020-07-31 | 2022-07-01 | 广东昭泰体内生物医药科技有限公司 | 一种car-nk细胞培养基及其应用 |
| WO2022090203A1 (en) | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| EP4232068A1 (en) | 2020-10-26 | 2023-08-30 | Cytune Pharma | IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
| TW202241470A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 治療人類個體腫瘤之方法 |
| TW202241471A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 提高個體中NKp30陽性淋巴球的方法及其用途 |
| WO2022197548A1 (en) | 2021-03-14 | 2022-09-22 | Rubius Therapeutics, Inc. | Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof |
| US20240254445A1 (en) * | 2021-06-01 | 2024-08-01 | Vaxcell-Bio | Composition containing feeder cell for proliferating natural killer cell |
| TW202317179A (zh) | 2021-06-03 | 2023-05-01 | 美商盧比亞斯治療公司 | 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法 |
| CN115595310A (zh) * | 2021-07-08 | 2023-01-13 | 中国医学科学院血液病医院（中国医学科学院血液学研究所）（Cn） | Nk细胞的滋养细胞、其制备方法和应用 |
| CN113599395B (zh) * | 2021-09-22 | 2022-08-12 | 郑州源创吉因实业有限公司 | 含有nk细胞的治疗癌症的药物组合物 |
| CN114113639B (zh) * | 2022-01-29 | 2022-04-19 | 北京大有天弘科技有限公司 | 一种血型抗体检测方法及其应用 |
| WO2023250484A2 (en) * | 2022-06-24 | 2023-12-28 | Emory University | Recombinant interleukin-37, chimeric antigen receptors, nucleic acids, and vectors encoding the same and uses in cancer therapies |
| JP2026503418A (ja) * | 2022-12-28 | 2026-01-29 | サイトナス セラピューティクス インコーポレイテッド | 癌を治療するための組成物及び方法 |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| CN116789795A (zh) * | 2023-06-21 | 2023-09-22 | 广州奥科生物医学科技有限公司 | 一种将外源过表达蛋白锚定细胞膜上的多肽及应用 |
| CN117304343B (zh) * | 2023-10-11 | 2024-05-07 | 北京景达生物科技有限公司 | Gpc3靶向的car-nk细胞的制备及其应用 |
| WO2025221669A1 (en) * | 2024-04-18 | 2025-10-23 | Promab Biotechnologies, Inc. | Fusion protein comprising il-12 and gm-csf |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327710A (en) | 1980-06-18 | 1982-05-04 | The United States Of America As Represented By The Secretary Of Agriculture | Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system |
| US4935223A (en) | 1988-08-04 | 1990-06-19 | Board Of Regents, The University Of Texas System | Labeled cells for use in imaging |
| DK0517986T3 (da) | 1991-06-14 | 1998-03-30 | Europ Communities | Transformerede erythrocytter, fremgangsmåde til fremstilling af samme og deres anvendelse i farmaceutiske præparater |
| EP0882448B1 (en) | 1997-05-05 | 2005-01-12 | DIDECO S.r.l. | Method of encapsulating biologically active agents within erythrocytes and apparatus therefor |
| US6495351B2 (en) | 2000-02-08 | 2002-12-17 | Gendel Limited | Loading system and method for using the same |
| DE10335833A1 (de) * | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| NZ569541A (en) * | 2006-01-13 | 2012-05-25 | Us Gov Health & Human Serv | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
| US20070243137A1 (en) | 2006-04-18 | 2007-10-18 | Nanoprobes, Inc. | Cell and sub-cell methods for imaging and therapy |
| NZ599338A (en) * | 2007-06-27 | 2013-11-29 | Marinepolymer Tech Inc | Complexes of il-15 and il-15ralpha and uses thereof |
| FR2919804B1 (fr) * | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
| US20100040546A1 (en) | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| EP2686420B1 (en) | 2011-03-18 | 2017-03-01 | New York Blood Center, Inc. | Megakaryocyte and platelet production from stem cells |
| EP2994491A4 (en) | 2013-05-10 | 2016-12-07 | Whitehead Inst Biomedical Res | IN VITRO PREPARATION OF ERYTHROCYTES WITH SORTASE-PROOF PROTEINS |
| WO2014183066A2 (en) | 2013-05-10 | 2014-11-13 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| CA2930665A1 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| MA39819A (fr) | 2014-04-01 | 2017-02-08 | Rubius Therapeutics Inc | Méthodes et compositions d'immunomodulation |
| CA2945388A1 (en) * | 2014-04-23 | 2015-10-29 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
| EP3390643B8 (en) * | 2015-12-18 | 2023-08-02 | OncoSec Medical Incorporated | Plasmid constructs for heterologous protein expression and methods of use |
| KR20180096789A (ko) | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| SI3402491T1 (sl) * | 2016-01-11 | 2022-05-31 | Rubius Therapeutics, Inc. | Sestavki in postopki v zvezi z multimodalnimi terapevtskimi celičnimi sistemi za indikacije raka |
| MX2019000205A (es) | 2016-07-07 | 2019-09-23 | Rubius Therapeutics Inc | Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno. |
| CN106755107B (zh) * | 2016-11-22 | 2019-10-01 | 上海健信生物医药科技有限公司 | 一种car新分子及其在肿瘤治疗中的应用 |
| US20180153989A1 (en) | 2016-12-02 | 2018-06-07 | Rubius Therapeutics, Inc. | Compositions and methods related to cell systems for penetrating solid tumors |
| CN110520522A (zh) | 2017-02-17 | 2019-11-29 | 鲁比厄斯治疗法股份有限公司 | 功能化红系细胞 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| CN112105723A (zh) | 2018-03-08 | 2020-12-18 | 鲁比厄斯治疗法股份有限公司 | 用于治疗癌症和传染病的治疗性细胞系统和方法 |
-
2019
- 2019-03-08 CN CN201980030291.XA patent/CN112105723A/zh active Pending
- 2019-03-08 KR KR1020207029027A patent/KR20200140279A/ko not_active Withdrawn
- 2019-03-08 EP EP19713277.2A patent/EP3762422A1/en not_active Withdrawn
- 2019-03-08 WO PCT/US2019/021490 patent/WO2019173798A1/en not_active Ceased
- 2019-03-08 JP JP2020547001A patent/JP2021514665A/ja active Pending
- 2019-03-08 AU AU2019232012A patent/AU2019232012A1/en not_active Withdrawn
- 2019-03-08 US US16/297,540 patent/US11141433B2/en not_active Expired - Fee Related
- 2019-03-08 RU RU2020132924A patent/RU2020132924A/ru unknown
- 2019-03-08 MX MX2020009359A patent/MX2020009359A/es unknown
- 2019-03-08 SG SG11202008261WA patent/SG11202008261WA/en unknown
- 2019-03-08 CA CA3093387A patent/CA3093387A1/en active Pending
-
2020
- 2020-09-06 IL IL277159A patent/IL277159A/en unknown
-
2021
- 2021-09-27 US US17/486,537 patent/US20220088076A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11141433B2 (en) | 2021-10-12 |
| KR20200140279A (ko) | 2020-12-15 |
| WO2019173798A1 (en) | 2019-09-12 |
| JP2021514665A (ja) | 2021-06-17 |
| MX2020009359A (es) | 2021-01-29 |
| EP3762422A1 (en) | 2021-01-13 |
| AU2019232012A1 (en) | 2020-09-24 |
| US20190298769A1 (en) | 2019-10-03 |
| CA3093387A1 (en) | 2019-09-12 |
| CN112105723A (zh) | 2020-12-18 |
| US20220088076A1 (en) | 2022-03-24 |
| SG11202008261WA (en) | 2020-09-29 |
| IL277159A (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020132924A (ru) | Терапевтические клеточные системы и способы лечения рака и инфекционных заболеваний | |
| JP2021514665A5 (enExample) | ||
| JP7000315B2 (ja) | 高結合活性ｈｐｖ ｔ細胞受容体 | |
| Hsieh et al. | Pathogen-induced Th1 phenotype development in CD4+ αβ-TCR transgenic T cells is macrophage dependent | |
| CN110997903B (zh) | 用于癌症治疗的t细胞的活化方法 | |
| Alsaieedi et al. | Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells | |
| JP2021525534A5 (enExample) | ||
| CA3090512A1 (en) | Tethered interleukin-15 and interleukin-21 | |
| KR20110129945A (ko) | ＩｇＥ 시그날 펩티드 및/또는 ＩＬ-15를 암호화하는 핵산 서열 및 이를 포함하는 조성물 및 이를 사용하는 방법 | |
| JP2023539871A5 (enExample) | ||
| WO2024183413A1 (zh) | 一种辐照car-t细胞及其制备方法与应用 | |
| PT1869166E (pt) | Produção in vitro de uma população de células usando células alimentadoras | |
| Shen et al. | A tumor-specific Th2 clone initiating tumor rejection via primed CD8+ cytotoxic T-lymphocyte activation in mice | |
| JP2024532876A (ja) | プライマリー免疫細胞を作製するための方法 | |
| JP2022512540A5 (enExample) | ||
| US20250144211A1 (en) | Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding | |
| CN117106061B (zh) | 靶向巨细胞病毒抗原的tcr和表达其的t细胞及应用 | |
| CN121379966A (zh) | 一种新型免疫细胞的制备方法及其应用 | |
| EP4252759B1 (en) | T cell receptors targeting pik3ca mutations and uses thereof | |
| CN114555815A (zh) | T细胞受体及其使用方法 | |
| CN112111460A (zh) | 修饰的细胞群体的药物组合物 | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| KR102552440B1 (ko) | 암 치료를 위한 t 세포의 활성화 방법 | |
| WO2021092719A1 (zh) | 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白 | |
| WO2023205868A1 (pt) | Sequência de ácido nucleico que codifica um receptor de célula natural killer de antígeno quimérico (nk-car), polipeptídeo do referido nk car, vetor que compreende a referida sequência de ácido nucleico, método in vitro de obtenção de uma célula nk, uso dos referidos sequência de ácido nucleica, polipeptídeo ou vetor, e composição farmacêutica |